Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction

Table 3 Outcomes based on primary and secondary endpoints among study groups

	Routine	Delayed		P value
	Group A (≤ 24.0 h), n = 183	Group B (24.0 ≤ 48.0 h), n = 96	Group C (48.0–72.0 h), n = 58	Group A vs Group B	Group A vs Group C	Group B vs Group C
Primary outcomes, n (%)
MACCE	16 (8.7)	13 (13.5)	7 (12.06)	0.212	0.263	0.965
Secondary outcomes, n (%)
Death	5 (2.7)	2 (2.1)	1 (1.7)	0.999	0.999	0.999
Myocardial infarction	2 (1.1)	3 (3.1)	4 (6.9)	0.343	0.093	0.427
Target vessel revascularization	3 (1.6)	2 (2.1)	1 (1.7)	0.999	0.999	0.999
Congestive heart failure	6 (3.3)	6 (6.3)	1 (1.7)	0.245	0.999	0.256
Stroke	0	0	0	-	-	-
Major bleeding1	1 (0.5)	1 (1.0)	2 (3.4)	0.999	0.145	0.557

¹As defined by Bleeding Academic Research Consortium (BARC) classification.

MACCE: Major adverse cardiac and cerebrovascular events.